<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="44438"><DrugName>ciprofloxacin hydrochloride</DrugName><DrugNamesKey><Name id="43032838">Baycip</Name><Name id="43032839">Ciflox</Name><Name id="43057250">Ciloxan</Name><Name id="43032807">Cipro</Name><Name id="43032816">Ciprobay</Name><Name id="43032817">Ciproxan</Name><Name id="43032840">Ciproxin</Name><Name id="43032841">Ciproxina</Name><Name id="43032842">Ciproxine</Name><Name id="43032843">Uniflox</Name><Name id="42751334">ciprofloxacin</Name><Name id="42755028">ciprofloxacin hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>ciprofloxacin</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>ciprofloxacin hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>BAY-Q-3939</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Cipro</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ciprobay</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ciproxan</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Baycip</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ciflox</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ciproxin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ciproxina</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ciproxine</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Uniflox</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ciloxan</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>85721-33-1</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>86393-32-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14455">Bayer AG</CompanyOriginator><CompaniesPrimary><Company id="14455">Bayer AG</Company><Company id="1074773">Medsintez</Company><Company id="1061684">FUJIFILM Pharma Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="18077">Merck &amp; Co Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="44438" type="Drug"><TargetEntity id="90006" type="siDrug">Ciprofloxacin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1061684" type="Company"><TargetEntity id="5035553367" type="organizationId">Fujifilm Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="14455" type="Company"><TargetEntity id="4295869217" type="organizationId">Bayer AG</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="102" type="ciIndication"><TargetEntity id="10012735" type="MEDDRA"></TargetEntity><TargetEntity id="D003967" type="MeSH"></TargetEntity><TargetEntity id="-957779542" type="omicsDisease"></TargetEntity><TargetEntity id="380" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1075" type="ciIndication"><TargetEntity id="10061190" type="MEDDRA"></TargetEntity><TargetEntity id="D006192" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="116" type="ciIndication"><TargetEntity id="10051910" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"></TargetEntity><TargetEntity id="D029424" type="MeSH"></TargetEntity><TargetEntity id="-459670493" type="omicsDisease"></TargetEntity><TargetEntity id="277" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="120" type="ciIndication"><TargetEntity id="D004927" type="MeSH"></TargetEntity><TargetEntity id="-1969770508" type="omicsDisease"></TargetEntity><TargetEntity id="803" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="137" type="ciIndication"><TargetEntity id="D016905" type="MeSH"></TargetEntity><TargetEntity id="-409642348" type="omicsDisease"></TargetEntity><TargetEntity id="801" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1397" type="ciIndication"><TargetEntity id="A20.9" type="ICD10"></TargetEntity><TargetEntity id="A20.2" type="ICD10"></TargetEntity><TargetEntity id="A20" type="ICD10"></TargetEntity><TargetEntity id="A20.7" type="ICD10"></TargetEntity><TargetEntity id="020.9" type="ICD9"></TargetEntity><TargetEntity id="10053026" type="MEDDRA"></TargetEntity><TargetEntity id="D010930" type="MeSH"></TargetEntity><TargetEntity id="707" type="ORPHANET"></TargetEntity><TargetEntity id="-1890820985" type="omicsDisease"></TargetEntity><TargetEntity id="1651" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1434" type="ciIndication"><TargetEntity id="10051904" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1437" type="ciIndication"><TargetEntity id="10054876" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1438" type="ciIndication"><TargetEntity id="10061470" type="MEDDRA"></TargetEntity><TargetEntity id="D011512" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="1440" type="ciIndication"><TargetEntity id="10061512" type="MEDDRA"></TargetEntity><TargetEntity id="D016868" type="MeSH"></TargetEntity><TargetEntity id="-311564119" type="omicsDisease"></TargetEntity><TargetEntity id="4021" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1475" type="ciIndication"><TargetEntity id="A38" type="ICD10"></TargetEntity><TargetEntity id="034.1" type="ICD9"></TargetEntity></SourceEntity><SourceEntity id="1484" type="ciIndication"><TargetEntity id="10060693" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1487" type="ciIndication"><TargetEntity id="J20" type="ICD10"></TargetEntity><TargetEntity id="466.0" type="ICD9"></TargetEntity><TargetEntity id="279" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1493" type="ciIndication"><TargetEntity id="A03.1" type="ICD10"></TargetEntity><TargetEntity id="4020" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1494" type="ciIndication"><TargetEntity id="A03.3" type="ICD10"></TargetEntity></SourceEntity><SourceEntity id="1495" type="ciIndication"><TargetEntity id="A03.2" type="ICD10"></TargetEntity></SourceEntity><SourceEntity id="1496" type="ciIndication"><TargetEntity id="A03.0" type="ICD10"></TargetEntity><TargetEntity id="10051402" type="MEDDRA"></TargetEntity><TargetEntity id="D004403" type="MeSH"></TargetEntity><TargetEntity id="-670464952" type="omicsDisease"></TargetEntity><TargetEntity id="908" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1497" type="ciIndication"><TargetEntity id="2651" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1797" type="ciIndication"><TargetEntity id="N45.3" type="ICD10"></TargetEntity></SourceEntity><SourceEntity id="1798" type="ciIndication"><TargetEntity id="10054088" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1815" type="ciIndication"><TargetEntity id="J15" type="ICD10"></TargetEntity><TargetEntity id="10060946" type="MEDDRA"></TargetEntity><TargetEntity id="D018410" type="MeSH"></TargetEntity><TargetEntity id="-2031977293" type="omicsDisease"></TargetEntity><TargetEntity id="928" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="195" type="ciIndication"><TargetEntity id="4198" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="227" type="ciIndication"><TargetEntity id="A54" type="ICD10"></TargetEntity><TargetEntity id="10018612" type="MEDDRA"></TargetEntity><TargetEntity id="D006069" type="MeSH"></TargetEntity><TargetEntity id="-1597924426" type="omicsDisease"></TargetEntity><TargetEntity id="914" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="280" type="ciIndication"><TargetEntity id="804" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="284" type="ciIndication"><TargetEntity id="10037596" type="MEDDRA"></TargetEntity><TargetEntity id="D011704" type="MeSH"></TargetEntity><TargetEntity id="-721934222" type="omicsDisease"></TargetEntity><TargetEntity id="344" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2951" type="ciIndication"><TargetEntity id="10046480" type="MEDDRA"></TargetEntity><TargetEntity id="D014526" type="MeSH"></TargetEntity><TargetEntity id="-1620155457" type="omicsDisease"></TargetEntity><TargetEntity id="917" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2999" type="ciIndication"><TargetEntity id="J01" type="ICD10"></TargetEntity><TargetEntity id="461" type="ICD9"></TargetEntity><TargetEntity id="10001076" type="MEDDRA"></TargetEntity><TargetEntity id="303" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="309" type="ciIndication"><TargetEntity id="10058080" type="MEDDRA"></TargetEntity><TargetEntity id="D013203" type="MeSH"></TargetEntity><TargetEntity id="-967239129" type="omicsDisease"></TargetEntity><TargetEntity id="812" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3140" type="ciIndication"><TargetEntity id="10034254" type="MEDDRA"></TargetEntity><TargetEntity id="D000292" type="MeSH"></TargetEntity><TargetEntity id="-856114132" type="omicsDisease"></TargetEntity><TargetEntity id="1756" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3242" type="ciIndication"><TargetEntity id="H60" type="ICD10"></TargetEntity><TargetEntity id="10033072" type="MEDDRA"></TargetEntity><TargetEntity id="D010032" type="MeSH"></TargetEntity><TargetEntity id="-1601414498" type="omicsDisease"></TargetEntity><TargetEntity id="897" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="348" type="ciIndication"><TargetEntity id="A01.00" type="ICD10"></TargetEntity><TargetEntity id="10045275" type="MEDDRA"></TargetEntity><TargetEntity id="D014435" type="MeSH"></TargetEntity><TargetEntity id="-1620842464" type="omicsDisease"></TargetEntity><TargetEntity id="807" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="39" type="ciIndication"><TargetEntity id="A22" type="ICD10"></TargetEntity><TargetEntity id="022" type="ICD9"></TargetEntity><TargetEntity id="10002713" type="MEDDRA"></TargetEntity><TargetEntity id="D000881" type="MeSH"></TargetEntity><TargetEntity id="-1661981662" type="omicsDisease"></TargetEntity><TargetEntity id="809" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="394" type="ciIndication"><TargetEntity id="10033078" type="MEDDRA"></TargetEntity><TargetEntity id="D010033" type="MeSH"></TargetEntity><TargetEntity id="-2113735649" type="omicsDisease"></TargetEntity><TargetEntity id="898" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="403" type="ciIndication"><TargetEntity id="N30" type="ICD10"></TargetEntity><TargetEntity id="10011781" type="MEDDRA"></TargetEntity><TargetEntity id="D003556" type="MeSH"></TargetEntity><TargetEntity id="-1776447469" type="omicsDisease"></TargetEntity><TargetEntity id="941" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="456" type="ciIndication"><TargetEntity id="4196" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="473" type="ciIndication"><TargetEntity id="N41" type="ICD10"></TargetEntity><TargetEntity id="10036978" type="MEDDRA"></TargetEntity><TargetEntity id="D011472" type="MeSH"></TargetEntity><TargetEntity id="-636590603" type="omicsDisease"></TargetEntity><TargetEntity id="363" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="485" type="ciIndication"><TargetEntity id="D017192" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="554" type="ciIndication"><TargetEntity id="10005941" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="577" type="ciIndication"><TargetEntity id="10017964" type="MEDDRA"></TargetEntity><TargetEntity id="904" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="706" type="ciIndication"><TargetEntity id="10036898" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"></TargetEntity><TargetEntity id="10011762" type="MEDDRA"></TargetEntity><TargetEntity id="D003550" type="MeSH"></TargetEntity><TargetEntity id="586" type="ORPHANET"></TargetEntity><TargetEntity id="-1447400656" type="omicsDisease"></TargetEntity><TargetEntity id="288" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity></SourceEntity><SourceEntity id="9320" type="Action"><TargetEntity id="1498" type="Mechanism">DNA Topoisomerase IV Inhibitors</TargetEntity></SourceEntity><SourceEntity id="431" type="Action"><TargetEntity id="901" type="Mechanism">DNA Gyrase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00623" type="ciTarget"><TargetEntity id="59521" type="siTarget">DNA gyrase (bacterial)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Acute sinusitis - UK - Dec-1987</FirstLaunched><FirstLaunched>Bacillus anthracis infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Bacterial infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Bacterial infection - US - Dec-1987</FirstLaunched><FirstLaunched>Bacterial pneumonia - UK - Dec-1987</FirstLaunched><FirstLaunched>Bacterial respiratory tract infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Bacterial skin infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Bacterial urinary tract infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Bone and joint infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Chronic obstructive pulmonary disease - UK - Dec-1987</FirstLaunched><FirstLaunched>Cystic fibrosis - UK - Dec-1987</FirstLaunched><FirstLaunched>Diarrhea - UK - Dec-1987</FirstLaunched><FirstLaunched>Epididymo-orchitis - UK - Dec-1987</FirstLaunched><FirstLaunched>Gastrointestinal infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Gram negative bacterium infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Neisseria gonorrhoeae infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Neisseria meningitidis infection - UK - Dec-1987</FirstLaunched><FirstLaunched>Otitis externa - UK - Dec-1987</FirstLaunched><FirstLaunched>Otitis media - UK - Dec-1987</FirstLaunched><FirstLaunched>Pelvic inflammatory disease - UK - Dec-1987</FirstLaunched><FirstLaunched>Prophylaxis - UK - Dec-1987</FirstLaunched><FirstLaunched>Pyelonephritis - UK - Dec-1987</FirstLaunched><FirstLaunched>Urethritis - UK - Dec-1987</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="102">Diarrhea</Indication><Indication id="1075">Haemophilus infection</Indication><Indication id="116">Enterobacter infection</Indication><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="120">Escherichia coli infection</Indication><Indication id="137">Gram negative bacterium infection</Indication><Indication id="1394">Bacteroides fragilis infection</Indication><Indication id="1397">Yersinia pestis infection</Indication><Indication id="1434">Citrobacter infection</Indication><Indication id="1437">Morganella infection</Indication><Indication id="1438">Proteus infection</Indication><Indication id="1439">Providencia infection</Indication><Indication id="1440">Serratia infection</Indication><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="1455">Moraxella catarrhalis infection</Indication><Indication id="1475">Streptococcus pyogenes infection</Indication><Indication id="1482">Enterococcus faecalis infection</Indication><Indication id="1484">Bacterial respiratory tract infection</Indication><Indication id="1487">Acute bronchitis</Indication><Indication id="1493">Shigella flexneri infection</Indication><Indication id="1494">Shigella sonnei infection</Indication><Indication id="1495">Shigella boydii infection</Indication><Indication id="1496">Shigella dysenteriae infection</Indication><Indication id="1497">Campylobacter jejuni infection</Indication><Indication id="1797">Epididymo-orchitis</Indication><Indication id="1798">Bacterial urinary tract infection</Indication><Indication id="1815">Bacterial pneumonia</Indication><Indication id="195">Klebsiella pneumoniae infection</Indication><Indication id="227">Neisseria gonorrhoeae infection</Indication><Indication id="280">Pseudomonas aeruginosa infection</Indication><Indication id="284">Pyelonephritis</Indication><Indication id="2951">Urethritis</Indication><Indication id="2999">Acute sinusitis</Indication><Indication id="308">Staphylococcus aureus infection</Indication><Indication id="309">Staphylococcus infection</Indication><Indication id="313">Streptococcus pneumoniae infection</Indication><Indication id="3140">Pelvic inflammatory disease</Indication><Indication id="3242">Otitis externa</Indication><Indication id="348">Salmonella typhi infection</Indication><Indication id="389">Neisseria meningitidis infection</Indication><Indication id="39">Bacillus anthracis infection</Indication><Indication id="394">Otitis media</Indication><Indication id="40">Bacterial infection</Indication><Indication id="403">Cystitis</Indication><Indication id="456">Proteus mirabilis infection</Indication><Indication id="473">Prostatitis</Indication><Indication id="485">Bacterial skin infection</Indication><Indication id="554">Bone and joint infection</Indication><Indication id="577">Gastrointestinal infection</Indication><Indication id="706">Prophylaxis</Indication><Indication id="88">Cystic fibrosis</Indication></IndicationsPrimary><ActionsPrimary><Action id="431">DNA gyrase inhibitor</Action><Action id="9320">Topoisomerase IV inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="15187">Systemic dermatological antibacterial product</Action><Action id="1594">Antibacterial</Action><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="740">Infusion</Technology><Technology id="743">Granule</Technology><Technology id="751">Film coating</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-28T07:36:44.000Z</LastModificationDate><ChangeDateLast>2019-05-13T00:00:00.000Z</ChangeDateLast><AddedDate>2003-03-28T09:59:10.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by  &lt;ulink linkID="14455" linkType="Company"&gt;Bayer AG&lt;/ulink&gt;, and marketed in Japan by &lt;ulink linkID="1061684" linkType="Company"&gt;FUJIFILM Pharma&lt;/ulink&gt;, and previously in the US by &lt;ulink linkID="19711" linkType="Company"&gt;Schering-Plough&lt;/ulink&gt; (now &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt;), ciprofloxacin (Cipro; Ciprobay; Ciproxin, Ciproxan; Ciloxan) is a broad-spectrum fluoroquinolone antibiotic  available in oral and intravenous (iv) formulations [&lt;ulink linkID="507261" linkType="Reference"&gt;507261&lt;/ulink&gt;]. In the US, the tablet and oral solution formulations are indicated for the treatment of infections in adult patients caused by susceptible strains of the designated microorganisms in the following conditions: urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus or Enterococcus faecalis; acute uncomplicated cystitis in females caused by E coli or S saprophyticus; chronic bacterial prostatitis caused by E coli or P mirabilis, lower respiratory tract infections caused by E coli, K pneumoniae, E cloacae, P mirabilis, P aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae; acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis; acute sinusitis caused by H influenzae, penicillin-susceptible S pneumoniae or M catarrhalis; skin and skin structure infections caused by E coli, K pneumoniae, E cloacae, P mirabilis, Proteus vulgaris, Providencia stuartii, M morganii, C freundii, P aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible S epidermidis or Streptococcus pyogenes; bone and joint infections caused by E cloacae, S marcescens or P aeruginosa; complicated intra-abdominal infections (in combination with metronidazole) caused by E coli, P aeruginosa, P mirabilis, K pneumoniae or Bacteroides fragilis; infectious diarrhea caused by enterotoxigenic E coli, Campylobacter jejuni, Shigella boydii, Shigella dysenteriae, Shigella flexneri or Shigella sonnei; typhoid fever caused by Salmonella typhi; and uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. In pediatric patients aged 1 to 17 years, the drug is indicated for the treatment of complicated urinary tract infections and pyelonephritis caused by E coli. The oral formulations are also indicated in adult and pediatric patients for inhalational anthrax (post-exposure), to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis, and for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age   [&lt;ulink linkID="1129118" linkType="Reference"&gt;1129118&lt;/ulink&gt;]. In Japan, the oral formulation is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms (cyprofloxacin-sensitive Staphylococcus, Streptococcus, Pneumococcus, Enterococci, Neisseria gonorrhoeae, Anthrax, Escherichia coli, Shigella, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Haemophilus influenzae, Pseudomonas aeruginosa, Acinetobacter, Legionella and Peptostreptococcus) in the following conditions: secondary infections such as superficial skin infections, deep skin infections, lymphatic vessels / lymphadenitis, chronic pyoderma, trauma · burns and surgical wounds, mastitis, perianal abscess, pharynx / laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory disease, cystitis, pyelonephritis, prostatitis, epididymitis, urethritis, bile inflammation, bowel inflammation, Bartholinitis, intrauterine infection, uterine adnexitis, tearing blight , stomatitis, papillary adenitis, otitis media, sinusitis, anthrax and inflammation   [&lt;ulink linkID="1979743" linkType="Reference"&gt;1979743&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug is also available as an iv infusion, indicated in the US for the treatment of the following infections in adult patients: urinary tract infections caused by E coli (including cases with secondary bacteremia), K pneumoniae subspecies pneumoniae, E cloacae, S marcescens, P mirabilis, P rettgeri, M morganii, C diversus, C freundii, P aeruginosa, methicillin-susceptible S epidermidis, S saprophyticus or E faecalis; lower respiratory tract infections caused by E coli, K pneumoniae subspecies pneumoniae, E cloacae, P mirabilis, P aeruginosa, H influenzae, H parainfluenzae, or penicillin-susceptible S pneumoniae; acute exacerbations of chronic bronchitis caused by M catarrhalis; nosocomial pneumonia caused by H influenzae or K pneumoniae; skin and skin structure infections caused by E coli, K pneumoniae subspecies pneumoniae, E cloacae, P mirabilis, P vulgaris, P stuartii, M morganii, C freundii, P aeruginosa, methicillin-susceptible S aureus, methicillin-susceptible S epidermidis or S pyogenes; bone and joint infections caused by E cloacae, S marcescens or P aeruginosa; complicated intra-abdominal infections (in conjunction with metronidazole) caused by E coli, P aeruginosa, P mirabilis, K pneumoniae or B fragilis; acute sinusitis caused by H influenzae, penicillin-susceptible S pneumoniae or M catarrhalis; chronic bacterial prostatitis caused by E coli or P mirabilis; and empirical therapy for febrile neutropenic patients in combination with piperacillin sodium. In pediatric patients aged 1 to 17 years, iv ciprofloxacin is indicated for the treatment of complicated urinary tract infections and pyelonephritis caused by E coli. It is also indicated in adult and pediatric patients for inhalational anthrax (post-exposure), to reduce the incidence or progression of disease following exposure to aerosolized B anthracis, and for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age     [&lt;ulink linkID="1129125" linkType="Reference"&gt;1129125&lt;/ulink&gt;]. In Japan, the iv infusion formulation is indicated in adults for the treatment of infections caused by susceptible strains of the designated microorganisms (Staphylococcus, Enterococci, Anthrax, Escherichia coli, Klebsiella, Enterobacter, Pseudomonas aeruginosa and Legionella) for the following conditions:  sepsis, secondary infection, such as trauma, burns and surgical wounds, pneumonia, peritonitis, bile sac flame, cholangitis and anthrax; and in children for the treatment of infections caused by susceptible strains of the designated microorganisms (Anthrax which is sensitive to this drug, Escherichia coli and Pseudomonas aeruginosa) for the following conditions: complicated cystitis, respiratory infection  in cystic fibrosis patients, pyelonephritis and anthrax [&lt;ulink linkID="2113675" linkType="Reference"&gt;2113675&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the UK, the drug is available as granules for oral suspension and solution for iv infusion, indicated in adults for the treatment of lower respiratory tract infections caused by Gram-negative bacteria, exacerbations of chronic obstructive pulmonary disease, broncho-pulmonary infections in cystic fibrosis or in bronchiectasis, pneumonia, chronic suppurative otitis media, acute exacerbations of chronic sinusitis (in particular due to Gram-negative bacteria), urinary tract infections, gonococcal urethritis and cervicitis, epididymo-orchitis (including cases caused by Neisseria gonorrhoeae), pelvic inflammatory disease (including cases caused by N gonorrhoeae), gastrointestinal tract infections (including travelers' diarrhea), intra-abdominal infections, skin and soft tissue infections caused by Gram-negative bacteria, malignant external otitis, bone and joint infections, treatment and prophylaxis of infections in neutropenic patients, prophylaxis of invasive infections due to Neisseria meningitidis, and post-exposure prophylaxis and treatment of inhalation anthrax.  In children and adolescents, the drug is indicated for the treatment of broncho-pulmonary infections in cystic fibrosis caused by P aeruginosa, complicated urinary tract infections and pyelonephritis, and the post-exposure prophylaxis and treatment of inhalation anthrax [&lt;ulink linkID="1129133" linkType="Reference"&gt;1129133&lt;/ulink&gt;], [&lt;ulink linkID="1128994" linkType="Reference"&gt;1128994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 1987, ciprofloxacin was launched in the UK as an iv formulation and in the US as an oral tablet formulation [&lt;ulink linkID="1040879" linkType="Reference"&gt;1040879&lt;/ulink&gt;].  Oral ciprofloxacin was launched in Japan in July 1988 for bacterial infection [&lt;ulink linkID="1129165" linkType="Reference"&gt;1129165&lt;/ulink&gt;], [&lt;ulink linkID="1979743" linkType="Reference"&gt;1979743&lt;/ulink&gt;]. The iv and  oral suspension formulations were approved by the FDA in December 1990 and September 1997, respectively [&lt;ulink linkID="1129140" linkType="Reference"&gt;1129140&lt;/ulink&gt;], [&lt;ulink linkID="1128995" linkType="Reference"&gt;1128995&lt;/ulink&gt;]. The oral formulation was approved in the UK in April 1996 [&lt;ulink linkID="1129133" linkType="Reference"&gt;1129133&lt;/ulink&gt;]. The iv formulation was launched in Japan in 2000  [&lt;ulink linkID="558246" linkType="Reference"&gt;558246&lt;/ulink&gt;]. In February 2003, the oral formulation was launched in Portugal [&lt;ulink linkID="1368470" linkType="Reference"&gt;1368470&lt;/ulink&gt;]. In July 2008, the license for ciprofloxacin was extended to include the second- and third-line treatment of complicated urinary tract infections and pyelonephritis in pediatric patients aged 1 to 17 years in the UK [&lt;ulink linkID="923497" linkType="Reference"&gt;923497&lt;/ulink&gt;]. By June 2012, an additional dosage for severe infection was in phase III development  [&lt;ulink linkID="1304713" linkType="Reference"&gt;1304713&lt;/ulink&gt;]. In September 2015, Bayer received Japanese approval for a dosage change in adults and an additional indication for pediatric use, presumably for complicated cystitis. Also in September 2015, the 400-mg dose was approved as a new formulation [&lt;ulink linkID="1699031" linkType="Reference"&gt;1699031&lt;/ulink&gt;]. In February 2015, oral and iv ciprofloxacin was additionally approved for treatment and prophylaxis of plaque [&lt;ulink linkID="1729271" linkType="Reference"&gt;1729271&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Bayer and &lt;ulink linkID="21266" linkType="Company"&gt;Ranbaxy Laboratories&lt;/ulink&gt; also comarket &lt;ulink linkID="32696" linkType="Drug"&gt;Cipro XR&lt;/ulink&gt;, a once-daily, extended-release oral formulation of ciprofloxacin. Bayer was also developing an &lt;ulink linkID="52725" linkType="Drug"&gt;inhaled version&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In June 2003, &lt;ulink linkID="14354" linkType="Company"&gt;Barr Laboratories Inc&lt;/ulink&gt; began marketing a generic version of ciprofloxacin, following a license that resulted from a patent challenge in 1997. The patent was subsequently the subject of additional patent invalidity challenges litigated in the US district courts and in each instance, the validity of Bayer's patent was upheld [&lt;ulink linkID="654481" linkType="Reference"&gt;654481&lt;/ulink&gt;]. The US patent for Cipro expired in December 2003, however, a pediatric extension took the US expiry date to June 2004 [&lt;ulink linkID="523645" linkType="Reference"&gt;523645&lt;/ulink&gt;]. In September 2003, Bayer signed an agreement with Barr to allow it to continue distribution of generic ciprofloxacin during any period of pediatric exclusivity that may be granted [&lt;ulink linkID="507263" linkType="Reference"&gt;507263&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2004, the FDA approved several generic ciprofloxacin applications. As a result, a number of companies began immediately shipping generic ciprofloxacin tablets at strengths of 250, 500 and 750 mg. At that time, Dr Reddy's stated that it had 180-day market exclusivity for the 100-mg strength [&lt;ulink linkID="550705" linkType="Reference"&gt;550705&lt;/ulink&gt;], [&lt;ulink linkID="550706" linkType="Reference"&gt;550706&lt;/ulink&gt;], [&lt;ulink linkID="550707" linkType="Reference"&gt;550707&lt;/ulink&gt;], [&lt;ulink linkID="609930" linkType="Reference"&gt;609930&lt;/ulink&gt;]; Bayer was asserting that it would maintain a sizeable part of the ciprofloxacin business through &lt;ulink linkID="32696" linkType="Drug"&gt;Cipro XR&lt;/ulink&gt;, which had pediatric exclusivity to June 2006 [&lt;ulink linkID="527914" linkType="Reference"&gt;527914&lt;/ulink&gt;], [&lt;ulink linkID="558246" linkType="Reference"&gt;558246&lt;/ulink&gt;]. The FDA granted approval to several ANDAs for generic iv ciprofloxacin in August 2006 [&lt;ulink linkID="686530" linkType="Reference"&gt;686530&lt;/ulink&gt;]. In March 2007, Mylan launched its generic Cipro XR product in two strengths, 500 and 1000 mg [&lt;ulink linkID="784073" linkType="Reference"&gt;784073&lt;/ulink&gt;]. In November 2009, &lt;ulink linkID="1003828" linkType="Company"&gt;Westward&lt;/ulink&gt; was granted FDA approval for its generic product [&lt;ulink linkID="1064995" linkType="Reference"&gt;1064995&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2014, &lt;ulink linkID="21932" linkType="Company"&gt;Lupin Pharmaceuticals&lt;/ulink&gt; had received final US approval for its generic ciprofloxacin for oral suspension (250 mg/5 ml and 500 mg/5 ml); as the first applicant to file an ANDA for Cipro oral suspension, Lupin was entitled to 180 days of marketing exclusivity. Lupin subsequently launched its generic oral suspension  [&lt;ulink linkID="1571145" linkType="Reference"&gt;1571145&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Intravenous formulation&lt;/subtitle&gt;The iv formulation was approved by the FDA in December 1990 [&lt;ulink linkID="1128995" linkType="Reference"&gt;1128995&lt;/ulink&gt;]. In February 2015, iv ciprofloxacin was additionally approved for treatment and prophylaxis of plaque [&lt;ulink linkID="1729271" linkType="Reference"&gt;1729271&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Oral formulation&lt;/subtitle&gt;The tablet formulation of ciprofloxacin was  approved in October 1987, and had been launched by the end of that year [&lt;ulink linkID="1129139" linkType="Reference"&gt;1129139&lt;/ulink&gt;], [&lt;ulink linkID="1040879" linkType="Reference"&gt;1040879&lt;/ulink&gt;]. In February 2015, oral ciprofloxacin was additionally approved for treatment and prophylaxis of plaque [&lt;ulink linkID="1729271" linkType="Reference"&gt;1729271&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;The oral suspension was approved by the FDA in September 1997 [&lt;ulink linkID="1129140" linkType="Reference"&gt;1129140&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Intravenous formulation&lt;/subtitle&gt;Ciprofloxacin (iv) was  approved in the UK in February 1987, and had been launched by the end of that year [&lt;ulink linkID="1128994" linkType="Reference"&gt;1128994&lt;/ulink&gt;],  [&lt;ulink linkID="1040879" linkType="Reference"&gt;1040879&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Oral formulation&lt;/subtitle&gt;The oral formulation was approved in the UK in April 1996 [&lt;ulink linkID="1129133" linkType="Reference"&gt;1129133&lt;/ulink&gt;].  In February 2003, the oral formulation was launched in Portugal [&lt;ulink linkID="1368470" linkType="Reference"&gt;1368470&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2008, the license for ciprofloxacin was extended to include the second- and third-line treatment of complicated urinary tract infections and pyelonephritis in pediatric patients aged 1 to 17 years in the UK [&lt;ulink linkID="923497" linkType="Reference"&gt;923497&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Intravenous formulation&lt;/subtitle&gt;The iv formulation was launched in Japan in 2000  [&lt;ulink linkID="558246" linkType="Reference"&gt;558246&lt;/ulink&gt;]. In October 2014, Bayer filed for Japanese approval for complicated cystitis and pyelonephritis, and cystic fibrosis for pediatric use, and applied for a partial change in the dosage and administration for adult use [&lt;ulink linkID="1607030" linkType="Reference"&gt;1607030&lt;/ulink&gt;]. In August 2015, the drug application for pediatric complicated cystitis was recommended for approval by the second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council [&lt;ulink linkID="1690724" linkType="Reference"&gt;1690724&lt;/ulink&gt;]. In September 2015, Bayer received Japanese approval for a dosage change in adults and an additional indication for pediatric use, presumably for complicated cystitis and symptoms associated with respiratory infection  in cystic fibrosis patients. Also in September 2015, the 400-mg dose was approved as a new formulation [&lt;ulink linkID="1699031" linkType="Reference"&gt;1699031&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Oral formulation&lt;/subtitle&gt;Ciprofloxacin was launched in July 1988. The product is  is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms (cyprofloxacin-sensitive Staphylococcus, Streptococcus, Pneumococcus, Enterococci, Neisseria gonorrhoeae, Anthrax, Escherichia coli, Shigella, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Haemophilus influenzae, Pseudomonas aeruginosa, Acinetobacter, Legionella and Peptostreptococcus) in the following conditions: secondary infections such as superficial skin infections, deep skin infections, lymphatic vessels / lymphadenitis, chronic pyoderma, trauma · burns and surgical wounds, mastitis, perianal abscess, pharynx / laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory disease, cystitis, pyelonephritis, prostatitis, epididymitis, urethritis, bile inflammation, bowel inflammation, Bartholinitis, intrauterine infection, uterine adnexitis, tearing blight , stomatitis, papillary adenitis, otitis media, sinusitis, anthrax and inflammation [&lt;ulink linkID="1129165" linkType="Reference"&gt;1129165&lt;/ulink&gt;], [&lt;ulink linkID="1979743" linkType="Reference"&gt;1979743&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In May 2000, Ciprobay was approved in China; it was assumed that the drug was launched shortly after [&lt;ulink linkID="1286093" linkType="Reference"&gt;1286093&lt;/ulink&gt;], [&lt;ulink linkID="1286094" linkType="Reference"&gt;1286094&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;By April 2017, the drug had been launched in Russia [&lt;ulink linkID="2168603" linkType="Reference"&gt;2168603&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In October 1999, the product was approved in Taiwan; it was assumed that launch took place shortly after [&lt;ulink linkID="1526203" linkType="Reference"&gt;1526203&lt;/ulink&gt;], [&lt;ulink linkID="1524454" linkType="Reference"&gt;1524454&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 1999, it appeared that the Ciprobay tablet was approved in Korea. In November 2001, approval seemed to have been  obtained for the injectable formulation  [&lt;ulink linkID="1747964" linkType="Reference"&gt;1747964&lt;/ulink&gt;]. By February 2007, the drug was available in Korea as Ciprobay [&lt;ulink linkID="931392" linkType="Reference"&gt;931392&lt;/ulink&gt;], [&lt;ulink linkID="1939977" linkType="Reference"&gt;1939977&lt;/ulink&gt;]. By May 2008, the Korean FDA had requested for the labeling to include "adverse reactions could be caused by drug interaction with the CYP450 1A2 inhibitor &lt;ulink linkID="4908" linkType="Drug"&gt;ropinirole&lt;/ulink&gt;" [&lt;ulink linkID="967637" linkType="Reference"&gt;967637&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By November 2012, an injectable infusion  and coated tablet formulation of the drug was approved in Brazil [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;]. By November 2017, had been launched in Brazil [&lt;ulink linkID="2136122" linkType="Reference"&gt;2136122&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In July 2008, the FDA notified manufacturers of fluoroquinolone antimicrobial drugs, including Cipro, that a boxed warning  concerning the increased risk of tendinitis and tendon rupture was necessary [&lt;ulink linkID="923602" linkType="Reference"&gt;923602&lt;/ulink&gt;]. The US label also carries a black box warning for worsening of myasthenia gravis symptoms [&lt;ulink linkID="1129118" linkType="Reference"&gt;1129118&lt;/ulink&gt;], [&lt;ulink linkID="1129125" linkType="Reference"&gt;1129125&lt;/ulink&gt;]. In July 2018, the FDA updated the safety labeling for fluoroquinolones, including ciprofloxacin, regarding mental health side effects and serious blood sugar disturbances; the mental health side effects to include are disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium. The Blood Glucose Disturbances label subsection  is now required to explicitly reflect the potential risk of coma with hypoglycemia [&lt;ulink linkID="2052785" linkType="Reference"&gt;2052785&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;A study published in February 2005 compared the efficacy of a 3-day regimen of &lt;ulink linkID="44284" linkType="Drug"&gt;amoxicillin + clavulanate&lt;/ulink&gt; to that of a three-day regimen of ciprofloxacin in the treatment of acute cystitis in women. Clinical cure was observed in 93 (58%) of 160 women treated with amoxicillin + clavulanate, compared with 124 (77%) of 162 women treated with ciprofloxacin [&lt;ulink linkID="589311" linkType="Reference"&gt;589311&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2013, Bayer reported that the company was donating ciprofloxacin to Project Health Opportunities for People Everywhere (HOPE) UK, a partner of Project HOPE (People-to-People Health Foundation) for the treatment of up to 40,000 patients in Zanzibar; at that time, more than 7000 units of ciprofloxacin tablets had been donated to the Ministry of Health in Zanzibar [&lt;ulink linkID="1454996" linkType="Reference"&gt;1454996&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1497">Campylobacter jejuni infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1494">Shigella sonnei infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1455">Moraxella catarrhalis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1439">Providencia infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="1286094" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2015-09-24T00:00:00.000Z</StatusDate><Source id="1699031" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1075">Haemophilus infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1434">Citrobacter infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2951">Urethritis</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2951">Urethritis</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>1988-07-31T00:00:00.000Z</StatusDate><Source id="1979743" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1495">Shigella boydii infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1487">Acute bronchitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="39">Bacillus anthracis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1397">Yersinia pestis infection</Indication><StatusDate>2015-02-02T00:00:00.000Z</StatusDate><Source id="1729271" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2015-09-24T00:00:00.000Z</StatusDate><Source id="1699031" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="1286094" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="389">Neisseria meningitidis infection</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3242">Otitis externa</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2999">Acute sinusitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="1286094" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="389">Neisseria meningitidis infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2999">Acute sinusitis</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="309">Staphylococcus infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2999">Acute sinusitis</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="39">Bacillus anthracis infection</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="1286094" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1074773">Medsintez</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2017-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1496">Shigella dysenteriae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1440">Serratia infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2007-02-28T00:00:00.000Z</StatusDate><Source id="931392" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="706">Prophylaxis</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1797">Epididymo-orchitis</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>2000-12-31T00:00:00.000Z</StatusDate><Source id="1286094" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="348">Salmonella typhi infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3242">Otitis externa</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2017-11-08T00:00:00.000Z</StatusDate><Source id="2136122" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="389">Neisseria meningitidis infection</Indication><StatusDate>2003-02-25T00:00:00.000Z</StatusDate><Source id="1368470" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2017-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061684">FUJIFILM Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2012-06-27T00:00:00.000Z</StatusDate><Source id="1304727" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="577">Gastrointestinal infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1988-07-31T00:00:00.000Z</StatusDate><Source id="1979743" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="39">Bacillus anthracis infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2999">Acute sinusitis</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1437">Morganella infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1493">Shigella flexneri infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3140">Pelvic inflammatory disease</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="1040879" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2951">Urethritis</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1524454" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="120">Escherichia coli infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1440">Serratia infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1495">Shigella boydii infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1455">Moraxella catarrhalis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1438">Proteus infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2999">Acute sinusitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1487">Acute bronchitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1434">Citrobacter infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="473">Prostatitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="39">Bacillus anthracis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1497">Campylobacter jejuni infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1439">Providencia infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1075">Haemophilus infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="116">Enterobacter infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="309">Staphylococcus infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="348">Salmonella typhi infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1496">Shigella dysenteriae infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="554">Bone and joint infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="102">Diarrhea</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1437">Morganella infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1493">Shigella flexneri infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="403">Cystitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1494">Shigella sonnei infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="284">Pyelonephritis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate><Source id="1890872" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2000-05-27T00:00:00.000Z</StatusDate><Source id="1286093" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>2000-05-27T00:00:00.000Z</StatusDate><Source id="1286093" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>2000-05-27T00:00:00.000Z</StatusDate><Source id="1286093" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2000-05-27T00:00:00.000Z</StatusDate><Source id="1286093" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="39">Bacillus anthracis infection</Indication><StatusDate>2000-05-27T00:00:00.000Z</StatusDate><Source id="1286093" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="389">Neisseria meningitidis infection</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2999">Acute sinusitis</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2951">Urethritis</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3242">Otitis externa</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1990-10-08T00:00:00.000Z</StatusDate><Source id="1526203" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2014-10-30T00:00:00.000Z</StatusDate><Source id="1607030" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2015-09-24T00:00:00.000Z</StatusDate><Source id="1699031" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1397">Yersinia pestis infection</Indication><StatusDate>2015-02-02T00:00:00.000Z</StatusDate><Source id="1729271" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1440">Serratia infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1439">Providencia infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1437">Morganella infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1434">Citrobacter infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="309">Staphylococcus infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1075">Haemophilus infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1487">Acute bronchitis</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1455">Moraxella catarrhalis infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2999">Acute sinusitis</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1497">Campylobacter jejuni infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1495">Shigella boydii infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1496">Shigella dysenteriae infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1493">Shigella flexneri infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1494">Shigella sonnei infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="348">Salmonella typhi infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="39">Bacillus anthracis infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1440">Serratia infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1439">Providencia infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1437">Morganella infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1434">Citrobacter infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="309">Staphylococcus infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1075">Haemophilus infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1487">Acute bronchitis</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1455">Moraxella catarrhalis infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2999">Acute sinusitis</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1497">Campylobacter jejuni infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1495">Shigella boydii infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1496">Shigella dysenteriae infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1493">Shigella flexneri infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1494">Shigella sonnei infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="348">Salmonella typhi infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="39">Bacillus anthracis infection</Indication><StatusDate>2004-09-13T00:00:00.000Z</StatusDate><Source id="559382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2014-10-30T00:00:00.000Z</StatusDate><Source id="1607030" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2012-11-07T00:00:00.000Z</StatusDate><Source id="1338375" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1074773">Medsintez</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2012-11-07T00:00:00.000Z</StatusDate><Source id="1338375" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00623"><Name>DNA gyrase</Name><SwissprotNumbers><Swissprot>O08399</Swissprot><Swissprot>O29720</Swissprot><Swissprot>O33149</Swissprot><Swissprot>O33367</Swissprot><Swissprot>O33926</Swissprot><Swissprot>O50627</Swissprot><Swissprot>O50628</Swissprot><Swissprot>O51396</Swissprot><Swissprot>O51859</Swissprot><Swissprot>O67108</Swissprot><Swissprot>O67137</Swissprot><Swissprot>O83051</Swissprot><Swissprot>O84192</Swissprot><Swissprot>O84193</Swissprot><Swissprot>O87545</Swissprot><Swissprot>O87667</Swissprot><Swissprot>P05652</Swissprot><Swissprot>P05653</Swissprot><Swissprot>P0A0K7</Swissprot><Swissprot>P0A0K8</Swissprot><Swissprot>P0A2I3</Swissprot><Swissprot>P0A2I4</Swissprot><Swissprot>P0A4L9</Swissprot><Swissprot>P0A4M0</Swissprot><Swissprot>P0AES4</Swissprot><Swissprot>P0AES6</Swissprot><Swissprot>P0C0Q9</Swissprot><Swissprot>P0C0R0</Swissprot><Swissprot>P0C559</Swissprot><Swissprot>P0C5C5</Swissprot><Swissprot>P13364</Swissprot><Swissprot>P14829</Swissprot><Swissprot>P20831</Swissprot><Swissprot>P21557</Swissprot><Swissprot>P21558</Swissprot><Swissprot>P22118</Swissprot><Swissprot>P22446</Swissprot><Swissprot>P22447</Swissprot><Swissprot>P22840</Swissprot><Swissprot>P29435</Swissprot><Swissprot>P31860</Swissprot><Swissprot>P33769</Swissprot><Swissprot>P34030</Swissprot><Swissprot>P34031</Swissprot><Swissprot>P35810</Swissprot><Swissprot>P35885</Swissprot><Swissprot>P35886</Swissprot><Swissprot>P37411</Swissprot><Swissprot>P41080</Swissprot><Swissprot>P41513</Swissprot><Swissprot>P43053</Swissprot><Swissprot>P43700</Swissprot><Swissprot>P43701</Swissprot><Swissprot>P47235</Swissprot><Swissprot>P47249</Swissprot><Swissprot>P47250</Swissprot><Swissprot>P47719</Swissprot><Swissprot>P47720</Swissprot><Swissprot>P48354</Swissprot><Swissprot>P48369</Swissprot><Swissprot>P48370</Swissprot><Swissprot>P48371</Swissprot><Swissprot>P48372</Swissprot><Swissprot>P50028</Swissprot><Swissprot>P50071</Swissprot><Swissprot>P50074</Swissprot><Swissprot>P50075</Swissprot><Swissprot>P55992</Swissprot><Swissprot>P57126</Swissprot><Swissprot>P57277</Swissprot><Swissprot>P66936</Swissprot><Swissprot>P66937</Swissprot><Swissprot>P72065</Swissprot><Swissprot>P72524</Swissprot><Swissprot>P77966</Swissprot><Swissprot>P77993</Swissprot><Swissprot>P94281</Swissprot><Swissprot>P94604</Swissprot><Swissprot>P94605</Swissprot><Swissprot>Q03470</Swissprot><Swissprot>Q43907</Swissprot><Swissprot>Q43947</Swissprot><Swissprot>Q44065</Swissprot><Swissprot>Q44080</Swissprot><Swissprot>Q44081</Swissprot><Swissprot>Q44088</Swissprot><Swissprot>Q44270</Swissprot><Swissprot>Q44271</Swissprot><Swissprot>Q44272</Swissprot><Swissprot>Q44273</Swissprot><Swissprot>Q44274</Swissprot><Swissprot>Q44275</Swissprot><Swissprot>Q44276</Swissprot><Swissprot>Q44277</Swissprot><Swissprot>Q44278</Swissprot><Swissprot>Q49166</Swissprot><Swissprot>Q49467</Swissprot><Swissprot>Q49608</Swissprot><Swissprot>Q55738</Swissprot><Swissprot>Q57532</Swissprot><Swissprot>Q59533</Swissprot><Swissprot>Q5HJZ0</Swissprot><Swissprot>Q5HJZ1</Swissprot><Swissprot>Q5HK03</Swissprot><Swissprot>Q5HK04</Swissprot><Swissprot>Q5XC58</Swissprot><Swissprot>Q5XD05</Swissprot><Swissprot>Q6GD84</Swissprot><Swissprot>Q6GD85</Swissprot><Swissprot>Q6GKT9</Swissprot><Swissprot>Q6GKU0</Swissprot><Swissprot>Q89AS3</Swissprot><Swissprot>Q89B37</Swissprot><Swissprot>Q8CQK4</Swissprot><Swissprot>Q8DPM2</Swissprot><Swissprot>Q8K7H2</Swissprot><Swissprot>Q8K840</Swissprot><Swissprot>Q8K9W2</Swissprot><Swissprot>Q8NKW8</Swissprot><Swissprot>Q8P116</Swissprot><Swissprot>Q8P1M4</Swissprot><Swissprot>Q92H87</Swissprot><Swissprot>Q92IZ6</Swissprot><Swissprot>Q932M0</Swissprot><Swissprot>Q99XG5</Swissprot><Swissprot>Q9A0L0</Swissprot><Swissprot>Q9FAX1</Swissprot><Swissprot>Q9FAX2</Swissprot><Swissprot>Q9KVX3</Swissprot><Swissprot>Q9L7L3</Swissprot><Swissprot>Q9L7Q5</Swissprot><Swissprot>Q9LCK0</Swissprot><Swissprot>Q9LCK1</Swissprot><Swissprot>Q9PKK3</Swissprot><Swissprot>Q9PKK4</Swissprot><Swissprot>Q9PR63</Swissprot><Swissprot>Q9X3Y3</Swissprot><Swissprot>Q9X3Y5</Swissprot><Swissprot>Q9X3Y6</Swissprot><Swissprot>Q9Z8R3</Swissprot><Swissprot>Q9Z8R4</Swissprot><Swissprot>Q9ZAQ6</Swissprot><Swissprot>Q9ZCX2</Swissprot><Swissprot>Q9ZFK1</Swissprot><Swissprot>Q9ZLD9</Swissprot><Swissprot>Q9ZLX3</Swissprot></SwissprotNumbers></Target><Target id="PTGT-02147"><Name>Topoisomerase IV</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2167529" linkType="reference" linkID="2167529"&gt;2167529&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2167778" linkType="reference" linkID="2167778"&gt;2167778&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1028289">Lannett Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1037804">FUJIFILM Holdings Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1074773">Medsintez</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="14455">Bayer AG</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="15410">Chong Kun Dang Pharmaceutical Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24232">Spectrum Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1c2c(cc(c1F)N3CCNCC3)n(cc(c2=O)C(=O)O)C4CC4</Smiles><Smiles>c1c2c(cc(c1F)N3CCNCC3)n(cc(c2=O)C(=O)O)C4CC4.O.Cl</Smiles></StructureSmiles><Deals><Deal id="123247" title="Schering-Plough to market Bayer's ciprofloxacin in the US and Puerto Rico"/><Deal id="125906" title="Lannett to distribute Spectrum Pharmaceuticals' ciprofloxacin in the US"/><Deal id="140177" title="FUJIFILM Pharma to market Bayer Yakuhin's Glucobay, Ciproxan and Avelox in Japan "/><Deal id="142456" title="Medsintez to manufacture Bayer HealthCare's imaging products and pharmaceuticals for infections and neural disorders in Russia "/><Deal id="192462" title="Avelox and Ciprobay, diagnostic imaging products, and Nimotop in Russia"/><Deal id="240892" title="Chong Kun Dang to copromote Bayer's oral and iv formulations of Ciprobay in Korea"/></Deals><PatentFamilies><PatentFamily id="1016549" number="EP-00657448" title="One pot process for the preparation of 3-quinolonecarboxylic acid derivatives."/><PatentFamily id="103969" number="JP-2003104891" title="The pharmaceutical composition of a ciprofloxacin hydrochloride"/><PatentFamily id="1057044" number="EP-00669129" title="Expandable release controlled medicaments"/><PatentFamily id="1071308" number="WO-2008002118" title="An ophthalmic formulation in suspension of loteprednol etabonate and ciprofloxacin hydrochloride"/><PatentFamily id="1141629" number="WO-2005046692" title="Treatment of genetic diseases with the aid of quinolones, naphthyridones"/><PatentFamily id="1200327" number="EP-00287926" title="Process For The Preparation Of Quinoline Carboxylic Acids For Parenteral Application"/><PatentFamily id="1201298" number="EP-00202493" title="Process For The Preparation Of 5-Fluorotoluene-2,4-Disulfochloride"/><PatentFamily id="1208523" number="WO-09932156" title="Novel sterilization process for pharmaceutical suspensions."/><PatentFamily id="1208864" number="WO-09811860" title="Thermoplastic Polyurethanes Containing Active Substances"/><PatentFamily id="1275120" number="EP-00138018" title="Lösungen milchsaurer Salze von Piperazinylchinolon- und Piperazinyl-azachinoloncarbonsäuren"/><PatentFamily id="1275316" number="EP-00230881" title="Pharmaceutical preparations containing ciprofloxacin."/><PatentFamily id="1314133" number="EP-00551820" title="Taste-masked pharmaceutical compositions"/><PatentFamily id="1407660" number="WO-2010041112" title="Novel combinations of antibacterial nitrogenous heterocyclic compounds with other antibacterial compounds, and use thereof as drugs"/><PatentFamily id="1465208" number="EP-01067974" title="Moulded bodies made of thermoplastic polyurethane containing an active substance"/><PatentFamily id="1538406" number="WO-2007101560" title="Medicament formulations comprising fluoroquinolones"/><PatentFamily id="1571574" number="EP-00224178" title="1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo-7(1-Piperazinyl)-3-Quinoline-Carboxylic Acids, Process For Their Preparation And Antibacterial Compositions Containing Them"/><PatentFamily id="1581782" number="EP-00049355" title="7-Amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridine(-quinoline)-3-carboxylic acids, process for their preparation and pharmaceutical compositions containing them."/><PatentFamily id="164130" number="EP-00359076" title="Ph-neutral aqueous solutions of quinolone-carboxylic acids."/><PatentFamily id="16804" number="EP-00295495" title="Ion Exchange Resins Loaded With Quinoline Carboxylic Acid Derivatives, Their Preparation And Use"/><PatentFamily id="1681191" number="WO-2006007354" title="Oral delivery systems comprising a drug/polymer complex"/><PatentFamily id="1682619" number="WO-09715354" title="Methods For Decomposing Quinolones And Naphthyridones"/><PatentFamily id="1756611" number="WO-2009087665" title="Novel gastroretentive drug delivery system"/><PatentFamily id="178821" number="WO-2004069253" title="Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones"/><PatentFamily id="1904039" number="WO-09608517" title="Water-Soluble Dextran Fatty Acid Esters And Their Use As Solubilisers"/><PatentFamily id="2014390" number="EP-00268053" title="Metal Salts Of 1-Cyclopropylquinolonecarboxylic Acids And Medicaments Containing Them"/><PatentFamily id="2014944" number="IN-00170657" title="Process For The Preparation Of Quinoline-3-Carboxylic Acid Derivatives"/><PatentFamily id="2377705" number="EP-00280915" title="Preparations for topical use of gyrase inhibitors in combination with corticosteroids."/><PatentFamily id="239276" number="EP-00165474" title="Immunostimulant Agent"/><PatentFamily id="2505870" number="WO-2013051036" title="Use of pharmaceutical composition for gastroretentive sustained and pulsatile drug delivery system"/><PatentFamily id="2512825" number="WO-2013054330" title="Foam formulations"/><PatentFamily id="2584615" number="CN-102973565" title="A kind of medicine composition comprising ciprofloxacin hydrochloride compound and preparation method thereof"/><PatentFamily id="2740720" number="IN-201100563" title="&lt;para&gt;Topical, vaginal, systemic and oral dosage forms containing serratiopeptidase&lt;/para&gt;"/><PatentFamily id="276905" number="WO-09807428" title="Orally applicable formulation of quinolone or naphthyridone carboxylic acids."/><PatentFamily id="2845667" number="UA-00080835" title="Method for manufacturing pharmaceutical composition based on ciprofloxacin hydrochloride and dexamethasone for ophthalmological and otological use"/><PatentFamily id="3062952" number="WO-2015168642" title="Drug-releasing device usable in mucosal body cavities"/><PatentFamily id="3063611" number="US-20150316568" title="Method for screening lyophilized parenteral formulations"/><PatentFamily id="3118759" number="CN-105232464" title="Ciprofloxacin liposome formulation and preparation method"/><PatentFamily id="313517" number="EP-00219784" title="Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-chinolon-3-carboxylic acid"/><PatentFamily id="3150048" number="IN-201402117" title="Bilayer tablet formulation used as gastro-floating drug delivery system comprises immediate layer containing ciprofloxacin or other antibacterial substances and floating layer containing misoprostol and other anti-ulcer drugs"/><PatentFamily id="342477" number="US-20090124632" title="Methods and kits related to the topical administration of quinolone antibiotics"/><PatentFamily id="3591175" number="CN-106511279" title="The porous structure of the carrier particle and preparation method and application thereof"/><PatentFamily id="3934960" number="CN-107569463" title="Ciprofloxacin hydrochloride gastric-floating tablet and preparation technology thereof"/><PatentFamily id="3943539" number="IN-201641019319" title="Hydrogel formulation used for treating bacterial infections, includes ciprofloxacin hydrochloride, polyethylene glycol-polypropylene glycol, polyethylene glycol-polypropylene glycol-polyethylene glycol triblock copolymer, and chitosan"/><PatentFamily id="3946550" number="CN-107638402" title="A ciprofloxacin hydrochloride tablet composition for resisting helicobacter pylori"/><PatentFamily id="3960737" number="CN-107669645" title="Preparation method of ciprofloxacin hydrochloride tablets"/><PatentFamily id="3974843" number="WO-2018042430" title="Coatings of hydroxyapatite nanoparticles"/><PatentFamily id="4207773" number="CN-108567754" title="Ciprofloxacin hydrochloride tablet and its preparation method"/><PatentFamily id="4264325" number="CN-108771660" title="Ciprofloxacin hydrochloride dry powder inhalant and its preparation method"/><PatentFamily id="434995" number="CN-01660099" title="Pharmaceutically stable ciprofloxacin hydrochloride preparation"/><PatentFamily id="4428240" number="WO-2019126579" title="Colchicine formulations and methods of use"/><PatentFamily id="4531929" number="CN-109761900" title="A preparation method of ciprofloxacin hydrochloride"/><PatentFamily id="455098" number="WO-2012127505" title="Improved process for the preparation of ciprofloxacin and its acid addition salts"/><PatentFamily id="461134" number="EP-00187315" title="Basic Quinolonecarboxylic-Acid Preparations"/><PatentFamily id="467441" number="JP-2000053563" title="Rapid Releasable Fine Granule Having Masked Bitterness"/><PatentFamily id="660141" number="CN-101851198" title="Preparation method of ciprofloxacin hydrochloride"/><PatentFamily id="679995" number="DE-03632222" title="Topisch Anwendbare Zubereitungen Von Gyrase-Inhibitoren"/><PatentFamily id="721240" number="WO-09639146" title="Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions."/><PatentFamily id="727297" number="WO-02058669" title="Solid phase dispersion of quinolone- or naphthyridonecarboxylic acids"/><PatentFamily id="792508" number="WO-09902160" title="High-purity ciprofloxacine solutions for infusion."/><PatentFamily id="797913" number="EP-00274033" title="Process For The Preparation Of Quinolinecarboxylic Acids"/><PatentFamily id="830092" number="EP-00461501" title="Process for the preparation of quinoline carboxylic acids."/><PatentFamily id="849724" number="US-20080300258" title="Anhydrous ciprofloxacin hydrochloride"/><PatentFamily id="91127" number="EP-00337231" title="I. m. injection forms of gyrase-inhibitors."/><PatentFamily id="93544" number="DE-04129309" title="Alkyllactamhaltige Wirkstoff-Formulierungen"/><PatentFamily id="974245" number="EP-00078362" title="1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazino-quinoline-3-carboxylic acids, process for their preparation and antibacterial agents containing them."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>12</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>42</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Yat-Sen University" id="1004360"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratorios Sophia" id="1010962"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Princeton Trade &amp; Technology Inc" id="1011602"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novaflux Biosciences Inc" id="1017635"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Reyoung Pharmaceutical Co Ltd China" id="1029191"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Jingxin Pharmaceutical Co Ltd" id="1030336"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novus Therapeutics Inc" id="1031349"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alphora Research Inc" id="1044128"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="OJSC Farmak" id="1052823"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Yet-sen Memorial Hospital of Sun Yet-sen University" id="1074905"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Pengyao Pharmaceutical Co Ltd" id="1075920"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhengzhou Houyi Pharmaceutical Co Ltd" id="1080789"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui Xinglonghai Medicine Co Ltd" id="1089735"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rxomeg Therapeutics LLC" id="1153856"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BASF SE" id="14356"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"/><CountAsOwner>32</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>32</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Council of Scientific and Industrial Research (India)" id="15561"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nestle SA" id="18477"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alcon Inc" id="18478"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebrew University of Jerusalem" id="20586"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>13</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>13</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tel Aviv University" id="25012"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Danbury Phamacal Inc" id="DOL1000027"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>